Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AlphaRx to Seek China Approval of Arthritis Drug Indaflex™

publication date: Feb 1, 2008

AlphaRx (OTCBB: ALRX) has begun applying for approval of Indaflex™ in China as a treatment for osteoarthritis, with hopes that the application will be complete by April 2008. If the request is accepted, AlphaRx will conduct a clinical trial of Indaflex™ in China, enrolling 240 patients in a two-arm trial that will treat patients for four weeks. AlphaRx anticipates that the trial will be finished by Q4 of 2008. Indaflex™ is a novel formulation of a standard therapy for osteoarthritis, indomethicin. More details...

Stock Symbol: (OTCBB:ALRX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital